How Syntekabio’s Supercomputing Enables AI-driven Drug Discovery
What is "supercomputing"? It refers to processing a massive quantity of complex data-intensive and computation-heavy problems often found in scientific …
From Our Partners
The Power of STB CLOUD in Remote AI Drug Discovery
STB CLOUD is Syntekabio’s latest cloud-based, fully automated AI platform. It’s designed for developers to engage in their drug discovery …
The State of A.I. Drug Discovery and Its Future: Small Molecules, Vaccines, and Antibodies
Artificial intelligence (A.I.) and big data in a synergistic integration have led to promising results in new drug development by …
Democratizing Early Drug Discovery through Artificial Intelligence: Interview with Syntekabio CEO Jongsun Jung
Before the age of modern drug discovery, the pharmaceutical industry had been plagued with uncertainty and processing challenges, including the …
Building Momentum for Global AI-driven Longevity Transformation
Today, Insilico Medicine, a leading player in artificial intelligence (AI)-driven drug discovery and longevity research, tops up its recent $60 …
This South Korean Company is at the Forefront of AI-driven Drug Discovery
There is a new generation of tech-savvy drug discovery companies, applying the power of artificial intelligence (AI) to accelerate and …
Targeted Protein Degradation: a New Approach to Small Molecule Therapeutics
There is a new wave of innovation that is sweeping through pharmaceutical drug discovery: targeted protein degradation (TPD). TPD is …
Combining AI and Quantum Mechanics to Improve Drug and Vaccine Discovery
The application of Artificial Intelligence (AI) to accelerate and improve drug discovery has been a growing trend for several years …
Breakthrough Technology Solving Characterization Challenges and Accelerating Biopharmaceutical Drug Development
High-Resolution Ion Mobility Mass Spectrometry (HRIM-MS) has emerged as a promising new separations technique in the biopharmaceutical and clinical market. …
